CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-15 | Cox John CEO & President | Gift | −10,000 | 222,179 | ||
| 2025-07-15 | Cox John CEO & President | Gift | −10,000 | 212,179 | ||
| 2025-07-15 | Cox John CEO & President | Gift | −10,000 | 202,179 | ||
| 2025-07-14 | Cox John CEO & President | Purchase | +100,000 | $9.11 | $911K | 242,179 |
| 2025-06-05 | Cox John CEO & President | Sale 10b5-1 | −4,060 | $13.35 | $54K | 142,179 |
| 2025-06-05 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −1,342 | $13.35 | $18K | 92,815 |
| 2025-06-05 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −146 | $13.35 | $2K | 95,911 |
| 2025-05-30 | HURWITZ EDWARD Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-05-30 | Lubner David Charles Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-05-30 | Rhodes Jason P Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-05-30 | Kersten Dirk Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-05-30 | Incerti Carlo Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-05-30 | Stehman-Breen Catherine Director | Grant or award · Stock option (right to buy) | +35,000 | 35,000 | ||
| 2025-03-31 | Lucera Erick Chief Financial Officer | Grant or award | +66,100 | 66,100 | ||
| 2025-03-31 | Lucera Erick Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +214,500 | 214,500 | ||
| 2025-03-13 | Friedl-Naderer Johanna Chief Commercial Officer | Sale 10b5-1 | −143 | $12.12 | $2K | 96,057 |
| 2025-03-11 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −1,343 | $11.38 | $15K | 122,330 |
| 2025-03-11 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −2,153 | $11.38 | $25K | 195,840 |
| 2025-03-05 | Kerr Douglas Chief Medical Officer | Sale 10b5-1 | −1,343 | $11.83 | $16K | 94,157 |
| 2025-03-05 | Cox John CEO & President | Sale 10b5-1 | −4,061 | $11.83 | $48K | 146,239 |
Page 9 of 29 · 561 trades